Javascript must be enabled to continue!
Abstract 281: pH-sensitive liposome for siRNA delivery to treat drug-resistant ovarian cancer
View through CrossRef
Abstract
Introduction: With a 5-year survival rate of 47%, ovarian cancer is the 5th leading cause of death amongst women worldwide. Over 75% of patients experience recurrence after initial treatment, indicating a need for improved treatment options. Drug resistance is a major barrier hindering the success of current treatment methods. Our study analyzes the characteristics of a stimuli-sensitive liposomal delivery system for combatting drug resistance. Our delivery system will deliver bioactive siRNAs targeting genes related to drug resistance, cell proliferation, and apoptosis. In this study, we investigate the characteristics of the liposomes to determine particle size, surface charge, and ability to encapsulate/bind both siRNAs. We also begin to investigate the delivery potential of the pH-sensitive liposomal formulation in vitro using ovarian cancer cell lines.
Methods: Empty and siRNA loaded cationic, pH-sensitive liposomes (CHEMS-LPs) were synthesized by the thin-film hydration method. Liposome size, zeta potential, and polydispersity index (PDI) were measured by dynamic light scattering (DLS). To measure siRNA encapsulation efficiency, fluorescently labeled siRNA was loaded into CHEMS-LPs and subjected to centrifugation to pellet the LPs. Fluorescence spectroscopy was used to detect siRNA in the supernatant. The toxicity of unloaded CHEMS-LPs was determined by an MTS assay using OVCAR3 (drug-sensitive) and OVCAR3-T40 (drug-resistant) human ovarian cancer cells.
Results: The size and zeta potential of blank and siRNA-loaded CHEMS-LPs were 97.88 ± 2.39 nm and 29.0 ± 2.00 mV, and 80.78 ± 0.77 nm and 13.1 ±1.66 mV, respectively. The positively charged zeta potential confirms the cationic nature of our liposomes. The PDI demonstrated that the liposomes were unimodal and monodisperse with PDI values of less than 0.300 for each formulation. In addition, siRNA was successfully bound to CHEMS-LPs through electrostatic interaction with the cationic lipid layer, resulting in an encapsulation efficiency of 99.6%
Conclusion: CHEMS-LPs are pH-sensitive, cationic, monodisperse liposomes able to encapsulate siRNAs in order to mediate delivery into ovarian cancer cells. Their stable structure, positive charge, and low cytotoxicity is promising for future studies, including delivery of bioactive siRNAs to stimulate downregulation of target genes related to drug resistance.
Acknowledgements: This work was supported in part by the National Science Foundation EPSCoR Program under Award # OIA-1655740. We would like to thank George Duran from Stanford University for donating the OVCAR3-T40 cell line.
Citation Format: Kharimat Lora Alatise, Samantha Gardner, Angela Alexander-Bryant. pH-sensitive liposome for siRNA delivery to treat drug-resistant ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 281.
American Association for Cancer Research (AACR)
Title: Abstract 281: pH-sensitive liposome for siRNA delivery to treat drug-resistant ovarian cancer
Description:
Abstract
Introduction: With a 5-year survival rate of 47%, ovarian cancer is the 5th leading cause of death amongst women worldwide.
Over 75% of patients experience recurrence after initial treatment, indicating a need for improved treatment options.
Drug resistance is a major barrier hindering the success of current treatment methods.
Our study analyzes the characteristics of a stimuli-sensitive liposomal delivery system for combatting drug resistance.
Our delivery system will deliver bioactive siRNAs targeting genes related to drug resistance, cell proliferation, and apoptosis.
In this study, we investigate the characteristics of the liposomes to determine particle size, surface charge, and ability to encapsulate/bind both siRNAs.
We also begin to investigate the delivery potential of the pH-sensitive liposomal formulation in vitro using ovarian cancer cell lines.
Methods: Empty and siRNA loaded cationic, pH-sensitive liposomes (CHEMS-LPs) were synthesized by the thin-film hydration method.
Liposome size, zeta potential, and polydispersity index (PDI) were measured by dynamic light scattering (DLS).
To measure siRNA encapsulation efficiency, fluorescently labeled siRNA was loaded into CHEMS-LPs and subjected to centrifugation to pellet the LPs.
Fluorescence spectroscopy was used to detect siRNA in the supernatant.
The toxicity of unloaded CHEMS-LPs was determined by an MTS assay using OVCAR3 (drug-sensitive) and OVCAR3-T40 (drug-resistant) human ovarian cancer cells.
Results: The size and zeta potential of blank and siRNA-loaded CHEMS-LPs were 97.
88 ± 2.
39 nm and 29.
0 ± 2.
00 mV, and 80.
78 ± 0.
77 nm and 13.
1 ±1.
66 mV, respectively.
The positively charged zeta potential confirms the cationic nature of our liposomes.
The PDI demonstrated that the liposomes were unimodal and monodisperse with PDI values of less than 0.
300 for each formulation.
In addition, siRNA was successfully bound to CHEMS-LPs through electrostatic interaction with the cationic lipid layer, resulting in an encapsulation efficiency of 99.
6%
Conclusion: CHEMS-LPs are pH-sensitive, cationic, monodisperse liposomes able to encapsulate siRNAs in order to mediate delivery into ovarian cancer cells.
Their stable structure, positive charge, and low cytotoxicity is promising for future studies, including delivery of bioactive siRNAs to stimulate downregulation of target genes related to drug resistance.
Acknowledgements: This work was supported in part by the National Science Foundation EPSCoR Program under Award # OIA-1655740.
We would like to thank George Duran from Stanford University for donating the OVCAR3-T40 cell line.
Citation Format: Kharimat Lora Alatise, Samantha Gardner, Angela Alexander-Bryant.
pH-sensitive liposome for siRNA delivery to treat drug-resistant ovarian cancer [abstract].
In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21.
Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 281.
Related Results
Abstract 4288: Targeted therapy against aldehyde dehydrogenase in ovarian cancer
Abstract 4288: Targeted therapy against aldehyde dehydrogenase in ovarian cancer
Abstract
OBJECTIVE. Aldehyde dehydrogenase-1 (ALDH1) expression characterizes a subpopulation of cells with enhanced tumor initiating and differentiating properties ...
Abstract IA31: Molecular epidemiology of ovarian cancer
Abstract IA31: Molecular epidemiology of ovarian cancer
Abstract
Epithelial ovarian cancer (EOC) accounts for 5% of all cancer deaths and is the fifth leading cause of cancer death in women in the United States. While the...
Abstract 1515: Combination siRNA and gene delivery to SKOV-3 cancer cells by a customizable HER2 targeted biopolymeric vector
Abstract 1515: Combination siRNA and gene delivery to SKOV-3 cancer cells by a customizable HER2 targeted biopolymeric vector
Abstract
INTRODUCTION: The major hurdle in successful targeted cancer gene therapy is the lack of a suitable gene delivery vehicle, leaving room for research into in...
Abstract B8: Molecular subtyping of epithelial ovarian cancer reveals connections to intrinsic breast cancer subtypes
Abstract B8: Molecular subtyping of epithelial ovarian cancer reveals connections to intrinsic breast cancer subtypes
Abstract
Aim: Epithelial ovarian cancer is one of the most lethal female cancers. It is a heterogeneous group of neoplasms and the different histologic subtypes are ...
Abstract MIP-048: SHORT-FORM RON KINASE AS A NOVEL THERAPEUTIC TARGET IN OVARIAN CANCER
Abstract MIP-048: SHORT-FORM RON KINASE AS A NOVEL THERAPEUTIC TARGET IN OVARIAN CANCER
Abstract
BACKGROUND: Although 70–80% of women respond to standard platinum-based chemotherapy, a majority of patients will develop recurrent platinum-resistant disea...
Abstract 1761: Dual inhibition of HSP27 and FAO as a novel therapeutic strategy for cisplatin-resistant ovarian cancer
Abstract 1761: Dual inhibition of HSP27 and FAO as a novel therapeutic strategy for cisplatin-resistant ovarian cancer
Abstract
Cisplatin is the most commonly employed chemotherapeutic drug for ovarian cancer treatment. However, most ovarian cancer patients experience recurrent cispl...
Abstract B81: Changing fertility factors affecting breast cancer in the Bahamas
Abstract B81: Changing fertility factors affecting breast cancer in the Bahamas
Abstract
Introduction: There are many factors that affect breast and ovarian cancer incidence. Genetics, obesity, parity, age at menarche, age at first pregnancy, an...
Abstract 306: Cationic cholesterol liposomes for combination therapy to treat drug-resistant ovarian cancer
Abstract 306: Cationic cholesterol liposomes for combination therapy to treat drug-resistant ovarian cancer
Abstract
Introduction: Ovarian cancer is the fifth leading cause of cancer mortality in women, with nearly 75% of women who respond to initial platinum-based chemoth...

